Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
Visual representation of drug distribution in a liposome system, highlighting the fractions used to calculate Encapsulation Efficiency (EE) versus Loading Capacity (LC)
The weight loss achieved with GLP-1 therapy appears central to hepatic benefits, as weight reduction of 710% consistently improves NAFLD across multiple intervention studies
The enhanced efficacy of combination therapy suggests a potential paradigm shift in PCOS treatment strategies, moving beyond traditional monotherapy approaches
A., and Walker, P
Efforts to develop alternative treatment strategies have been undertaken
US$ 28.73
US$ 27.25
US$ 26.00
US$ 27.51
US$ 20.70
